English  |  正體中文  |  简体中文  |  總筆數 :2817371  
造訪人次 :  27745267    線上人數 :  361
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"su k y"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 51-60 / 249 (共25頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-08-20T08:00:39Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-08-20T08:00:38Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; BIN-CHI LIAO; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-07-13T06:04:33Z Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; LEE JIH-HSIANG; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.
臺大學術典藏 2021-07-13T06:04:33Z Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.
臺大學術典藏 2021-07-13T06:04:30Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-07-13T06:04:27Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-07-06T08:49:46Z Improved Dried Blood Spot-Based Metabolomics Analysis by a Postcolumn Infused-Internal Standard Assisted Liquid Chromatography-Electrospray Ionization Mass Spectrometry Method Chepyala D.;Kuo H.-C.;Su K.-Y.;Liao H.-W.;Wang S.-Y.;Chepyala S.R.;Lin-Chau Chang;Kuo C.-H.; Chepyala D.; Kuo H.-C.; Su K.-Y.; Liao H.-W.; Wang S.-Y.; Chepyala S.R.; LIN-CHAU CHANG; Kuo C.-H.
臺大學術典藏 2021-06-24T01:53:52Z Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS Su K.-Y.; Yan B.-S.; HAO-CHIEH CHIU; Yu C.-J.; Chang S.-Y.; Jou R.; Liu J.-L.; Hsueh P.-R.; Yu S.-L.
臺大學術典藏 2021-06-04T06:23:06Z Improved Dried Blood Spot-Based Metabolomics Analysis by a Postcolumn Infused-Internal Standard Assisted Liquid Chromatography-Electrospray Ionization Mass Spectrometry Method Chepyala D.;Kuo H.-C.;Su K.-Y.;Liao H.-W.;Wang S.-Y.;Chepyala S.R.;Chang L.-C.;Ching-Hua Kuo; Chepyala D.; Kuo H.-C.; Su K.-Y.; Liao H.-W.; Wang S.-Y.; Chepyala S.R.; Chang L.-C.; CHING-HUA KUO
臺大學術典藏 2021-06-04T06:23:05Z Metabolomics Investigation of Voriconazole-Induced Hepatotoxicity in Mice Wu S.-L.;Wei T.-Y.;Lin S.-W.;Su K.-Y.;Ching-Hua Kuo; Wu S.-L.; Wei T.-Y.; Lin S.-W.; Su K.-Y.; CHING-HUA KUO

顯示項目 51-60 / 249 (共25頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目